See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
Abramson Cancer Center, West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.
Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakosen E, Valdes-Albini F, Chan A, Clark AS, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E: Management of Adverse Events in Patients with HER2+ Metastatic Breast Cancer Treated with Tucatinib, Trastuzumab, and Capecitabine (HER2CLIMB)
ASCO Annual Meeting : 2020 .
McAndew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A: Early Treatment-Related Neutropenia Predicts Response to Palbociclib British Journal of Cancer : 2020.
McDonald ES, Doot RK, Young AJ, Schubert EK, Tchou J, Pryma DA, Farwell MD, Nayak A, Ziober A, Feldman MD, DeMichele A, Clark AS, Shah PD, Lee H, Carlin SD, Mach RH, Mankoff DA: Breast Cancer 18 F-ISO-1 Uptake as a Marker of Proliferation Status The Journal of Nuclear Medicine : 2020.
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Issacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium: MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial Journal of Clinical Oncology : 2020.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chein AJ, Forero-Torres A, Ellis E, Han H, Clark AS, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kremmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ: Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial JAMA Oncology : 2020.
Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah PD, Clark AS, Fox K, Matro JM, Bradbury AR, Knollman H, Getz KD, Armenian SH, Januzzi JL, Tang WHW, Liu P, KY B: Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction Journal of the American Heart Association : 2020.
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndy L, Domchek S, DeMichele A, Fox K, Shah PD, Clark AS, Bradbury A, Matro JM, Adusumallo S, Carver JR, Ky B: Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy JACC: Cardiovascular Imaging : 2020.
Esserman L, Yeee D, DeMichele A, Yau C, Issacs C, Symmans WF, Albain K, Chen Yunn-yi, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocoo A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Yang S, Adams A, Chein AJ, Forero-Torres T, Stringer-Reasor E, Wallace AM, Pusztai L, Boughry JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Visvcusi RK, Euhus DM, Edison KK, Chi AY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Layland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, van 't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paolini M, Clennel JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Beery DA: Disease-free survival correlates with pathologic complete response in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer The Lancet : 2020.
McDonald E, Doot RK, Carlin SD, Pantel A, Shah PD, Clark AS, Desai H, Kelly G, Young AJ, Pryma DA, Farewell MD, Nayak A, Lee H, Schubert EK, Makvandi M, Xiober A, Tchou J, DeMichele A, Feldman M, Domchek SM, Mach RH, Maxwell KN, Manoff: PARP Imaging in Breast Bancer JAMA Oncology : 2020.
Clark AS,: Refining the indications for neoadjuvant chemotherapy (NAC) for patients with HER2+ breast cancer – a single institution experience Journal of Surgical Oncology : 2020.
Division of Hematology Oncology Perelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-1543400 Civic Center Boulevard
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.